Creo Medical Group (LON:CREO) Stock Price Down 1.8% – Here’s What Happened

Creo Medical Group PLC (LON:CREO)’s share price dropped 1.8% during mid-day trading on Friday. The stock traded as low as GBX 11.05 and last traded at GBX 11.05. Approximately 175,788 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 787,611 shares. The stock had previously closed at GBX 11.25.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating and issued a GBX 40 target price on shares of Creo Medical Group in a research report on Thursday, July 23rd.

Creo Medical Group Trading Down 1.8%

The stock has a market capitalization of £49.63 million, a price-to-earnings ratio of -2.21 and a beta of 1.56. The company has a debt-to-equity ratio of 8.09, a quick ratio of 2.19 and a current ratio of 2.79. The business has a 50-day moving average of GBX 11.86 and a 200-day moving average of GBX 12.66.

Creo Medical Group (LON:CREO) last issued its quarterly earnings results on Wednesday, September 30th. The company reported GBX (2) earnings per share for the quarter. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%. As a group, research analysts forecast that Creo Medical Group PLC will post -10.08 EPS for the current year.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.